Murray Potter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Murray Potter has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Anna Aihua Li
Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
3 shared publicationsFeng Shen
Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
2 shared publications- Aizeddin A. Mhanni
Children’s Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada
1 shared publication - Anne-Marie Laberge
Department of Social and Preventive Medicine, School of Public Health University of Montréal Montreal Canada
1 shared publication - Annette Feigenbaum
Department of Pediatrics, Division of Clinical & Metabolic Genetics, The Hospital for Sick Children and University of Toronto, Toronto, Canada
1 shared publication - Astrid Guttmann
Edwin S.H. Leong Centre for Healthy Children, University of Toronto, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 22 March 2019
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 14 (1) , 70
Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada
We describe early health services utilization for children diagnosed with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency through newborn screening in Ontario, Canada, relative to a screen negative comparison cohort. Eligible children were identified via newborn screening between April 1, 2006 and March 31, 2010. Age-stratified rates of physician encounters, emergency department (ED) visits and inpatient hospitalizations to March 31, 2012 were compared using incidence rate ratios (IRR) and incidence rate differences (IRD). We used negative binomial regression to adjust IRRs for sex, gestational age, birth weight, socioeconomic status and rural/urban residence. Throughout the first few years of life, children with MCAD deficiency (n = 40) experienced statistically significantly higher rates of physician encounters, ED visits, and hospital stays compared with the screen negative cohort. The highest rates of ED visits and hospitalizations in the MCAD deficiency cohort occurred from 6 months to 2 years of age (ED use: 2.1–2.5 visits per child per year; hospitalization: 0.5–0.6 visits per child per year), after which rates gradually declined. This study confirms that young children with MCAD deficiency use health services more frequently than the general population throughout the first few years of life. Rates of service use in this population gradually diminish after 24 months of age.
- 22 March 2019
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 14 (1) , 70
Open AccessHealth services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada
We describe early health services utilization for children diagnosed with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency through newborn screening in Ontario, Canada, relative to a screen negative comparison cohort. Eligible children were identified via newborn screening between April 1, 2006 and March 31, 2010. Age-stratified rates of physician encounters, emergency department (ED) visits and inpatient hospitalizations to March 31, 2012 were compared using incidence rate ratios (IRR) and incidence rate differences (IRD). We used negative binomial regression to adjust IRRs for sex, gestational age, birth weight, socioeconomic status and rural/urban residence. Throughout the first few years of life, children with MCAD deficiency (n = 40) experienced statistically significantly higher rates of physician encounters, ED visits, and hospital stays compared with the screen negative cohort. The highest rates of ED visits and hospitalizations in the MCAD deficiency cohort occurred from 6 months to 2 years of age (ED use: 2.1–2.5 visits per child per year; hospitalization: 0.5–0.6 visits per child per year), after which rates gradually declined. This study confirms that young children with MCAD deficiency use health services more frequently than the general population throughout the first few years of life. Rates of service use in this population gradually diminish after 24 months of age.
- 1 January 2009
- Published by Taylor & Francis in Artificial Cells, Blood Substitutes, and Biotechnology
- Vol. 37 (6) , 235-244
Luciferase Therapeutic Microcapsules for Gene Therapy
MDCK cells were engineered to express luciferase driven by cytomegalovirus (CMV) or hybrid ubiquitin B (UbB) promoter and encapsulated in alginate-poly-L-lysine-alginate microcapsules. In vitro experiments showed capsules could be monitored individually or in multi-layers quantitatively. When luciferase-expressing and non-luciferase expressing MDCK cells were mixed at different ratios and encapsulated, the signals increased linearly according to the number of capsules, in vitro and in vivo. For CMV-driven luciferase expression, the strongest signal was seen at 4 hours post-implantation, with a subsequent 50% decrease by 24 hours and then declined gradually to 10-20% until day 20. However, retrieved capsules showed good cell viability. When capsules contained plasmid driven by UbB promoter, there was no decline in signal. Our results indicate that luciferase could be used as a marker for microencapsulated cells to monitor the viability and gene expression of the implanted cells.
- 1 January 2009
- Published by Taylor & Francis in Artificial Cells, Blood Substitutes, and Biotechnology
- Vol. 37 (6) , 235-244
Luciferase Therapeutic Microcapsules for Gene Therapy
MDCK cells were engineered to express luciferase driven by cytomegalovirus (CMV) or hybrid ubiquitin B (UbB) promoter and encapsulated in alginate-poly-L-lysine-alginate microcapsules. In vitro experiments showed capsules could be monitored individually or in multi-layers quantitatively. When luciferase-expressing and non-luciferase expressing MDCK cells were mixed at different ratios and encapsulated, the signals increased linearly according to the number of capsules, in vitro and in vivo. For CMV-driven luciferase expression, the strongest signal was seen at 4 hours post-implantation, with a subsequent 50% decrease by 24 hours and then declined gradually to 10-20% until day 20. However, retrieved capsules showed good cell viability. When capsules contained plasmid driven by UbB promoter, there was no decline in signal. Our results indicate that luciferase could be used as a marker for microencapsulated cells to monitor the viability and gene expression of the implanted cells.
- 17 December 2008
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 90B (1) , 350-361
Mechanically enhanced microcapsules for cellular gene therapy
Microcapsules bearing a covalently cross‐linked coating have been developed for cellular gene therapy as an improvement on alginate‐poly(L‐lysine)‐alginate (APA) microcapsules that only have ionic cross‐linking. In this study, two mutually reactive polyelectrolytes, a polycation (designated C70), poly([2‐(methacryloyloxy)ethyl]trimethylammonium chloride‐co‐2‐aminoethyl methacrylate hydrochloride) and a polyanion (designated A70), poly(sodium methacrylate‐co‐2‐(methacryloyloxy)ethyl acetoacetate), were used during the microcapsule fabrication. Ca‐alginate beads were sequentially laminated with C70, A70, poly(L‐lysine) (PLL), and alginate. The A70 reacts with both C70 and PLL to form a ∼30 μm thick covalently cross‐linked interpenetrating polymer network on the surface of the capsules. Confocal images confirmed the location of the C70/A70/PLL network and the stability of the network after 4 weeks implantation in mice. The mechanical and chemical resistance of the capsules was tested with a “stress test” where microcapsules were gently shaken in 0.003% EDTA for 15 min. APA capsules disappeared during this treatment, whereas the modified capsules, even those that had been retrieved from mice after 4‐weeks implantation, remained intact. Analysis of solutions passing through model flat membranes showed that the molecular weight cut‐off of alginate‐C70‐A70‐PLL‐alginate is similar to that of alginate‐PLL‐alginate. Recombinant cells encapsulated in APA and modified capsules were able to secrete luciferase into culture media. The modified capsules were found to capture some components of regular culture media used during preparation, causing an immune reaction in implanted mice, but use of UltraCulture serum‐free medium was found to prevent this immune reaction. In vivo biocompatibility of the new capsules was similar to the APA capsules, with no sign of clinical toxicity on complete blood counts and liver function tests. The increased stability of the covalently modified microcapsules coupled with the acceptable biocompatibility and permeability demonstrated their potential for use as immunoisolation devices in gene therapy. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2009
- 17 December 2008
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 90B (1) , 350-361
Mechanically enhanced microcapsules for cellular gene therapy
Microcapsules bearing a covalently cross‐linked coating have been developed for cellular gene therapy as an improvement on alginate‐poly(L‐lysine)‐alginate (APA) microcapsules that only have ionic cross‐linking. In this study, two mutually reactive polyelectrolytes, a polycation (designated C70), poly([2‐(methacryloyloxy)ethyl]trimethylammonium chloride‐co‐2‐aminoethyl methacrylate hydrochloride) and a polyanion (designated A70), poly(sodium methacrylate‐co‐2‐(methacryloyloxy)ethyl acetoacetate), were used during the microcapsule fabrication. Ca‐alginate beads were sequentially laminated with C70, A70, poly(L‐lysine) (PLL), and alginate. The A70 reacts with both C70 and PLL to form a ∼30 μm thick covalently cross‐linked interpenetrating polymer network on the surface of the capsules. Confocal images confirmed the location of the C70/A70/PLL network and the stability of the network after 4 weeks implantation in mice. The mechanical and chemical resistance of the capsules was tested with a “stress test” where microcapsules were gently shaken in 0.003% EDTA for 15 min. APA capsules disappeared during this treatment, whereas the modified capsules, even those that had been retrieved from mice after 4‐weeks implantation, remained intact. Analysis of solutions passing through model flat membranes showed that the molecular weight cut‐off of alginate‐C70‐A70‐PLL‐alginate is similar to that of alginate‐PLL‐alginate. Recombinant cells encapsulated in APA and modified capsules were able to secrete luciferase into culture media. The modified capsules were found to capture some components of regular culture media used during preparation, causing an immune reaction in implanted mice, but use of UltraCulture serum‐free medium was found to prevent this immune reaction. In vivo biocompatibility of the new capsules was similar to the APA capsules, with no sign of clinical toxicity on complete blood counts and liver function tests. The increased stability of the covalently modified microcapsules coupled with the acceptable biocompatibility and permeability demonstrated their potential for use as immunoisolation devices in gene therapy. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2009
- Open Access
- 24 September 2007
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 12 (1) , 271-280
Isolation of human foetal myoblasts and its application for microencapsulation
- 24 September 2007
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 12 (1) , 271-280
Open AccessIsolation of human foetal myoblasts and its application for microencapsulation
- 7 February 2006
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 77B (2) , 296-306
Enhancement of myoblast microencapsulation for gene therapy
One method of nonviral‐based gene therapy is to implant microencapsulated nonautologous cells genetically engineered to secrete the desired gene products. Encapsulating the cells within a biocompatible permselective hydrogel, such as alginate‐poly‐L‐lysine‐alginate (APA), protects the foreign cells from the host immune system while allowing diffusion of nutrients and the therapeutic gene products. An important consideration is which kind of cells is the best candidate for long‐term implantation. Our previous work has shown that proliferation and differentiation of encapsulated C2C12 myoblasts in vitro are significantly improved by inclusion of basic fibroblast growth factor (bFGF), insulin growth factor II (IGF‐II), and collagen within the microcapsules (“enhanced” capsules). However, the effects of such inclusions on the functional status of the microcapsules in vivo are unknown. Here we found that comparing the standard with the enhanced APA microcapsules; there was no difference in the rates of diffusion of recombinant products of different sizes, that is, human factor IX (FIX, 65 kDa), murine IgG (150 kDa), and a lysosomal enzyme, β‐glucuronidase (300 kDa), thus providing a key requirement of such an immunoprotective device. Furthermore, the creatine phosphokinase activity and myosin heavy chain staining (markers for differentiation of the myoblasts) and the cell number per capsule in the enhanced microcapsules indicated a higher degree of differentiation and proliferation when compared to the standard microcapsules, thus demonstrating an improved microenvironment for the encapsulated cells. Efficacy was tested in a melanoma cancer tumor model by treating tumor induced by B16‐F0/neu tumor cells in mice with myoblasts secreting angiostatin from either the standard or enhanced APA microcapsules. Mice treated with enhanced APA‐microcapsules had an 80% reduction in tumor volume at day 21 compared to a 70% reduction in those treated with standard APA‐microcapsules. In conclusion, enhancement of APA microcapsules with growth factors and collagen did not adversely affect their permeability property and therapeutic efficacy. However, the enhanced differentiation and viability of the encapsulated myoblasts in vivo should be advantageous for long‐term delivery with this method of gene therapy. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2006
- 7 February 2006
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 77B (2) , 296-306
Enhancement of myoblast microencapsulation for gene therapy
One method of nonviral‐based gene therapy is to implant microencapsulated nonautologous cells genetically engineered to secrete the desired gene products. Encapsulating the cells within a biocompatible permselective hydrogel, such as alginate‐poly‐L‐lysine‐alginate (APA), protects the foreign cells from the host immune system while allowing diffusion of nutrients and the therapeutic gene products. An important consideration is which kind of cells is the best candidate for long‐term implantation. Our previous work has shown that proliferation and differentiation of encapsulated C2C12 myoblasts in vitro are significantly improved by inclusion of basic fibroblast growth factor (bFGF), insulin growth factor II (IGF‐II), and collagen within the microcapsules (“enhanced” capsules). However, the effects of such inclusions on the functional status of the microcapsules in vivo are unknown. Here we found that comparing the standard with the enhanced APA microcapsules; there was no difference in the rates of diffusion of recombinant products of different sizes, that is, human factor IX (FIX, 65 kDa), murine IgG (150 kDa), and a lysosomal enzyme, β‐glucuronidase (300 kDa), thus providing a key requirement of such an immunoprotective device. Furthermore, the creatine phosphokinase activity and myosin heavy chain staining (markers for differentiation of the myoblasts) and the cell number per capsule in the enhanced microcapsules indicated a higher degree of differentiation and proliferation when compared to the standard microcapsules, thus demonstrating an improved microenvironment for the encapsulated cells. Efficacy was tested in a melanoma cancer tumor model by treating tumor induced by B16‐F0/neu tumor cells in mice with myoblasts secreting angiostatin from either the standard or enhanced APA microcapsules. Mice treated with enhanced APA‐microcapsules had an 80% reduction in tumor volume at day 21 compared to a 70% reduction in those treated with standard APA‐microcapsules. In conclusion, enhancement of APA microcapsules with growth factors and collagen did not adversely affect their permeability property and therapeutic efficacy. However, the enhanced differentiation and viability of the encapsulated myoblasts in vivo should be advantageous for long‐term delivery with this method of gene therapy. © 2006 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2006
- 15 July 2004
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 129A (1) , 77-82
Pregnancy in a healthy woman with untreated citrullinemia
We report the clinical and biochemical data on a second successful pregnancy in a woman with citrullinemia due to argininosuccinate synthetase deficiency (CTLN1). Despite very elevated plasma and urine citrulline and little or no measurable argininosuccinate synthetase enzyme activity on cultured skin fibroblasts, this 29‐year‐old woman, who was identified through newborn screening, has remained asymptomatic throughout her life. Mutation analysis has recently revealed that she is a compound heterozygote for a known and a novel mutation (IVS15‐1G > C and K310Q, respectively). Many newborn screening programs have recently been expanded to include citrullinemia and numerous asymptomatic hypercitrullinemic infants and children have been identified. It is now important to define prognostic indicators that will help with treatment decisions and genetic counseling for these patients. This patient, as the only citrullinemic adult who has been followed prospectively, contributes important information in this regard. In addition, her child was unaffected by the high citrulline levels demonstrated in amniotic fluid and breast milk suggesting that citrulline is not teratogenic. Although pregnancy is an important risk factor for women with CTLN1, it appears that females with citrullinemia can have normal pregnancy outcomes, as long as metabolic crisis is avoided.
- 15 July 2004
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 129A (1) , 77-82
Pregnancy in a healthy woman with untreated citrullinemia
We report the clinical and biochemical data on a second successful pregnancy in a woman with citrullinemia due to argininosuccinate synthetase deficiency (CTLN1). Despite very elevated plasma and urine citrulline and little or no measurable argininosuccinate synthetase enzyme activity on cultured skin fibroblasts, this 29‐year‐old woman, who was identified through newborn screening, has remained asymptomatic throughout her life. Mutation analysis has recently revealed that she is a compound heterozygote for a known and a novel mutation (IVS15‐1G > C and K310Q, respectively). Many newborn screening programs have recently been expanded to include citrullinemia and numerous asymptomatic hypercitrullinemic infants and children have been identified. It is now important to define prognostic indicators that will help with treatment decisions and genetic counseling for these patients. This patient, as the only citrullinemic adult who has been followed prospectively, contributes important information in this regard. In addition, her child was unaffected by the high citrulline levels demonstrated in amniotic fluid and breast milk suggesting that citrulline is not teratogenic. Although pregnancy is an important risk factor for women with CTLN1, it appears that females with citrullinemia can have normal pregnancy outcomes, as long as metabolic crisis is avoided.